Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Current therapy of Eisenmenger syndrome.

Literature DB >> 28066570

Current therapy of Eisenmenger syndrome.

Minsu Kim¹, Wook-Jin Chung¹.

Abstract

Entities: Disease

Year: 2016 PMID： 28066570 PMCID： PMC5179453 DOI： 10.21037/jtd.2016.11.27

Source DB: PubMed Journal: J Thorac Dis ISSN： 2072-1439 Impact factor: 2.895

× No keyword cloud information.

14 in total

1. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension.

Authors: Christian F Opitz; Roland Wensel; Jörg Winkler; Michael Halank; Leonhard Bruch; Franz-Xaver Kleber; Gert Höffken; Stefan D Anker; Abdissa Negassa; Stephan B Felix; Roland Hetzer; Ralf Ewert
Journal: Eur Heart J Date: 2005-05-11 Impact factor: 29.983

2. Effects of inhaled iloprost on exercise capacity, quality of life, and cardiac function in patients with pulmonary arterial hypertension secondary to congenital heart disease (the Eisenmenger syndrome) (from the EIGER Study).

Authors: Kwang Soo Cha; Kyoung Im Cho; Jeong Sook Seo; Jung Hyun Choi; Yong Hyun Park; Dong Heon Yang; Geu Ru Hong; Dong Soo Kim
Journal: Am J Cardiol Date: 2013-09-05 Impact factor: 2.778

3. Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger syndrome--a randomized, placebo-controlled, double-blind crossover study.

Authors: Saibal Mukhopadhyay; Srikanth Nathani; Jamal Yusuf; Devendra Shrimal; Sanjay Tyagi
Journal: Congenit Heart Dis Date: 2011 Sep-Oct Impact factor: 2.007

Review 4. Treat-to-target strategies in pulmonary arterial hypertension: the importance of using multiple goals.

Authors: O Sitbon; N Galiè
Journal: Eur Respir Rev Date: 2010-12

5. Functional class and targeted therapy are related to the survival in patients with pulmonary arterial hypertension.

Authors: Yae Min Park; Wook-Jin Chung; Deok Young Choi; Han Joo Baek; Sung Hwan Jung; In Suck Choi; Eak Kyun Shin
Journal: Yonsei Med J Date: 2014-11 Impact factor: 2.759

6. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients.

Authors: Gérald Simonneau; Nazzareno Galiè; Pavel Jansa; Gisela Martina Bohns Meyer; Hikmet Al-Hiti; Andjela Kusic-Pajic; Jean-Christophe Lemarié; Marius M Hoeper; Lewis J Rubin
Journal: Int J Cardiol Date: 2014-01-09 Impact factor: 4.164

Current therapy of Eisenmenger syndrome.

1. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension.

2. Effects of inhaled iloprost on exercise capacity, quality of life, and cardiac function in patients with pulmonary arterial hypertension secondary to congenital heart disease (the Eisenmenger syndrome) (from the EIGER Study).

3. Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger syndrome--a randomized, placebo-controlled, double-blind crossover study.

Review 4. Treat-to-target strategies in pulmonary arterial hypertension: the importance of using multiple goals.

5. Functional class and targeted therapy are related to the survival in patients with pulmonary arterial hypertension.

6. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients.

Review 7. Pathologic assessment of vasculopathies in pulmonary hypertension.

8. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension.

9. The effects of perioperative inhaled iloprost on pulmonary hypertension with congenital heart disease.

10. Baseline Characteristics of the Korean Registry of Pulmonary Arterial Hypertension.

Review 1. Pulmonary Hypertension in Heart Failure.